Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent filovirus vaccine
- Development stage
- Unknown
- Lead developer
- Sabin Vaccine Institute
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bivalent filovirus vaccine is a viral vector vaccine candidate designed to provide protection against two high-consequence pathogens: Sudan ebolavirus (SUDV) and Marburg virus (MARV). Developed by the Sabin Vaccine Institute in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine utilizes a monovalent chimpanzee adenovirus type 3 (ChAd3) platform for each of its two components. The mechanism of action involves the delivery of genetic sequences encoding the surface glycoproteins (GP) of SUDV and MARV into host cells. Once expressed, these antigens trigger robust humoral and cellular immune responses, including the production of neutralizing antibodies and the activation of T-cells. This vaccine is primarily indicated for the prevention of viral hemorrhagic fever in regions at risk for outbreaks of Sudan virus disease and Marburg virus disease. It is currently being evaluated in Phase 2 clinical trials in East Africa to assess its safety and immunogenicity in endemic populations.
- Other names
- Sabin bivalent filovirus vaccineChAd3 bivalent filovirus vaccineChAd-3 bivalent filovirus vaccineChAd 3 bivalent filovirus vaccineNIAID bivalent filovirus vaccine
02
Targets
PYG (Glycogen phosphorylase)Zaire ebolavirus glycoprotein
Beyond the preview
Go deeper on bivalent filovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent filovirus vaccine.